#	Pagina
attuale pagina	/open-h2020/projects/196376/index.html
-1	/open-h2020/projects/220888/index.html
-2	/open-h2020/projects/216121/index.html

Opendata, web and dolomites

REACTION

Evaluation of the efficacy and of the antiviral activity of T-705 (favipiravir) duringEbola virus infection in non-human primates humans

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

REACTION project word cloud

Explore the words cloud of the REACTION project. It provides you a very rough idea of what is the project "REACTION" about.

evaluation favipiravir inhibits flue propagation treat proven experimental emergency difficult infected region ongoing antiviral pandemic public replication therapies reported viral spread 2000 prevention vivo humanitarian prevent japan experts profile inhibit security tested gathered producer consultation effect containing africa crisis chemical cells adverse rna option toyoma mitigate 2014 social epidemic fujifilm therapeutic total exceeded medicine vaccine humans world commitment ebov patients safety vaccines health candidates excellent shown economic severe expertise hence september dimensions vitro outbreaks sociocultural approved gene immensely till influenza viruses interventions outbreak drug treatment curative deadliest extensively reaction stock ebola political shifted west date sept context upscale

Project "REACTION" data sheet

The following table provides information about the project.

Coordinator	INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE Organization address address: RUE DE TOLBIAC 101 city: PARIS postcode: 75654 website: www.inserm.fr contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	France [FR]
Project website	http://www.reaction-ebola.eu/
Total cost	2˙755˙719 €
EC max contribution	2˙575˙809 € (93%)
Programme	1. H2020-EU.3.1. (SOCIETAL CHALLENGES - Health, demographic change and well-being)
Code Call	H2020-Adhoc-2014-20
Funding Scheme	RIA
Starting year	2014
Duration (year-month-day)	from 2014-11-01 to 2017-10-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE Organization address address: RUE DE TOLBIAC 101 city: PARIS postcode: 75654 website: www.inserm.fr contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (PARIS)	coordinator	1˙240˙726.00
2	ASSOCIATION POUR LE DEVELOPPEMENT DE L'ENSEIGNEMENT ET DES RECHERCHES AUPRES DES UNIVERSITES, DES CENTRES DE RECHERCHE ET DES ENTREPRISES D'AQUITAINE ASSOCIATION POUR LE DEVELOPPEMENT DE L'ENSEIGNEMENT ET DES RECHERCHES AUPRES DES UNIVERSITES, DES CENTRES DE RECHERCHE ET DES ENTREPRISES D'AQUITAINE Organization address address: AVENUE DU DOCTEUR ALBERT SCHWEITZER - CENTRE CONDORCET 162 city: PESSAC postcode: 33608 website: www.adera.fr contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (PESSAC)	participant	477˙262.00
3	ECOLE NORMALE SUPERIEURE DE LYON ECOLE NORMALE SUPERIEURE DE LYON Organization address address: PARVIS RENE DESCARTES 15 city: LYON postcode: 69342 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (LYON)	participant	142˙500.00
4	UNIVERSITE CHEIKH ANTA DIOP DE DAKAR UNIVERSITE CHEIKH ANTA DIOP DE DAKAR Organization address address: Avenue Martin Luther King city: DAKAR FANN postcode: - website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	SN (DAKAR FANN)	participant	134˙375.00
5	DRUG DISCOVERY FACTORY BV DRUG DISCOVERY FACTORY BV Organization address address: JOOP GEESINKWEG 167 city: AMSTERDAM DUIVENRECHT postcode: 1114 AB website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (AMSTERDAM DUIVENRECHT)	participant	127˙062.00
6	UNIVERSITE D'AIX MARSEILLE UNIVERSITE D'AIX MARSEILLE Organization address address: Boulevard Charles Livon 58 city: Marseille postcode: 13284 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (Marseille)	participant	88˙500.00
7	RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG Organization address address: SEMINARSTRASSE 2 city: HEIDELBERG postcode: 69117 website: www.uni-heidelberg.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (HEIDELBERG)	participant	86˙250.00
8	INSTITUT PASTEUR INSTITUT PASTEUR Organization address address: RUE DU DOCTEUR ROUX 25-28 city: PARIS CEDEX 15 postcode: 75724 website: http://www.pasteur.fr contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (PARIS CEDEX 15)	participant	74˙025.00
9	UNIVERSITEIT VAN AMSTERDAM UNIVERSITEIT VAN AMSTERDAM Organization address address: SPUI 21 city: AMSTERDAM postcode: 1012WX website: www.uva.nl contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (AMSTERDAM)	participant	72˙359.00
10	BERNHARD-NOCHT-INSTITUT FUER TROPENMEDIZIN BERNHARD-NOCHT-INSTITUT FUER TROPENMEDIZIN Organization address address: BERNHARD NOCHT STRASSE 74 city: HAMBURG postcode: 20359 website: www.bni.uni-hamburg.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (HAMBURG)	participant	64˙250.00
11	Department of Health Department of Health Organization address address: Quarry House, Quarry Hill city: Leeds postcode: LS2 7UE website: www.dh.gov.uk contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (Leeds)	participant	64˙250.00
12	UNIVERSITEIT UTRECHT UNIVERSITEIT UTRECHT Organization address address: HEIDELBERGLAAN 8 city: UTRECHT postcode: 3584 CS website: www.uu.nl contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (UTRECHT)	participant	4˙250.00
13	FONDATION POUR L INSTITUT DE HAUTES ETUDES INTERNATIONALES ET DU DEVELOPPEMENT FONDATION POUR L INSTITUT DE HAUTES ETUDES INTERNATIONALES ET DU DEVELOPPEMENT Organization address address: MAISON DE LA PAIX CHEMIN EUGENE RIGOT 2 city: GENEVE postcode: 1202 website: www.graduateinstitute.ch contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	CH (GENEVE)	participant	0.00

Map

Project objective

The ongoing Ebola outbreak in West Africa is the largest and deadliest the world has ever seen. In September 2014, the number of EBOV cases exceeded the total of all cases from previous known outbreaks. Further, this public health crisis shifted into a complex emergency, with significant, social, economic, humanitarian, political and security dimensions. Till date, no effective medicine has been proven to be effective against EBOV. As a result, it is immensely difficult to mitigate the current outbreak as well as prevent further outbreaks in this region. On Sept 4-5 2014, the WHO gathered expertise on experimental therapies and vaccines and their role in containing the Ebola outbreak in West Africa. During this consultation, experts identified several therapeutic and vaccine interventions that should be the focus of priority evaluation. Among these candidates is the existing antiviral drug Favipiravir, that has proven activity against many RNA viruses in vivo and in vitro including Ebola. Favipiravir is known to inhibit viral gene replication within infected cells to prevent propagation among which it inhibits viral gene replication within infected cells to prevent propagation. Hence, Favipiravir is currently aimed as a curative option in severe pandemic flue. Furthermore, there is currently enough stock of Favipiravir to even treat more than 20.000 patients, and the producer of Favipiravir, Toyoma Chemical/Fujifilm in Japan is willing to rapidly upscale the production of this drug. This drug has been extensively tested in humans and approved in Japan for treatment and prevention of influenza. The drug has shown an excellent safety profile in more than 2000 patients tested and no major adverse effect were reported. The current crisis requires both an immediate response to treat patients and prevent the further spread of the epidemic, as well as long term commitment in the complex sociocultural context. REACTION! will address both needs.

Deliverables

List of deliverables.
All approvals package	Documents, reports	2019-05-30 12:44:45
Software prediction Favipiravir treatment	Other	2019-05-30 12:44:47
Intervention draft	Demonstrators, pilots, prototypes	2019-05-30 12:44:49
report effect Favipiravir in mice	Documents, reports	2019-05-30 12:44:27
Active dissemination	Documents, reports	2019-05-30 12:44:45
Report 2 educational activities and surveys REACTION!	Documents, reports	2019-05-30 12:44:42
Report on the antiviral efficacy of Favipiravir in humans	Documents, reports	2019-05-30 12:44:38
Manuscript 1	Documents, reports	2019-05-30 12:44:48
Publication scientific papers	Documents, reports	2019-05-30 12:44:45
Report modviro-immunological markers in NHPs	Documents, reports	2019-05-30 12:44:29
Special issue	Documents, reports	2019-05-30 12:44:26
scientific documents on website plus discussion forum launch	Documents, reports	2019-05-30 12:44:42
Manual and toolkit	Documents, reports	2019-05-30 12:44:48
Report on Symposium	Documents, reports	2019-05-30 12:44:48
Manuscript 2	Documents, reports	2019-05-30 12:44:47
publication 2	Documents, reports	2019-05-30 12:44:27
publication 1	Documents, reports	2019-05-30 12:44:29
Report 1 educational activities and surveys REACTION!	Documents, reports	2019-05-30 12:44:42

Take a look to the deliverables list in detail: detailed list of REACTION deliverables.

Publications

List of publications.
year	authors and title	journal	last update
2017	Nathan Peiffer-Smadja, Ramatou Ouedraogo, Eric D\'Ortenzio, Papa Ndiaga CissÃ©, Zahra Zeggani, Abdoul Habib Beavogui, Sylvain Landry Faye, FrÃ©dÃ©ric Le Marcis, Yazdan Yazdanpanah, Vinh-Kim Nguyen Vaccination and blood sampling acceptability during Ramadan fasting month: A cross-sectional study in Conakry, Guinea published pages: 2569-2574, ISSN: 0264-410X, DOI: 10.1016/j.vaccine.2017.03.068	Vaccine 35/19	2019-07-02
2016	Daouda Sissoko, Cedric Laouenan, Elin Folkesson, Abdoul-Bing Mâ€™Lebing, Abdoul-Habib Beavogui, Sylvain Baize, Alseny-Modet Camara, Piet Maes, Susan Shepherd, Christine Danel, Sara Carazo, Mamoudou N. Conde, Jean-Luc Gala, GÃ©raldine Colin, HÃ©lÃ¨ne Savini, Joseph Akoi Bore, Frederic Le Marcis, Fara Raymond Koundouno, FrÃ©dÃ©ric Petitjean, Marie-Claire Lamah, Sandra Diederich, Alexis Tounkara, Gee Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea published pages: e1001967, ISSN: 1549-1676, DOI: 10.1371/journal.pmed.1001967	PLOS Medicine 13/3	2019-07-02
2018	FrÃ©dÃ©ric Le Marcis, Daouda Sissoko, Xavier Anglaret and Denis Malvy Doing Science in an Emergency. Challenging clinical trial standards and producing care. published pages: , ISSN: , DOI:	Localizing Standards	2019-07-02
2017	Thi Huyen Tram Nguyen, JÃ©rÃ©mie Guedj, Xavier Anglaret, CÃ©dric LaouÃ©nan, Vincent Madelain, Anne-Marie Taburet, Sylvain Baize, Daouda Sissoko, Boris Pastorino, Anne Rodallec, GÃ©raldine Piorkowski, Sara Carazo, Mamoudou N. Conde, Jean-Luc Gala, Joseph Akoi Bore, Caroline Carbonnelle, FrÃ©dÃ©ric Jacquot, HervÃ© Raoul, Denis Malvy, Xavier de Lamballerie, France MentrÃ© Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted published pages: e0005389, ISSN: 1935-2735, DOI: 10.1371/journal.pntd.0005389	PLOS Neglected Tropical Diseases 11/2	2019-07-02
2015	FrÃ©dÃ©ric LeÂ Marcis Â«Â Traiter les corps comme des fagotsÂ Â» Production sociale de lâ€™indiffÃ©rence en contexte Ebola (GuinÃ©e) published pages: , ISSN: 2111-5028, DOI: 10.4000/anthropologiesante.1907	Anthropologie et SantÃ© 11	2019-07-02
2017	Sophie Duraffour, Denis Malvy, Daouda Sissoko How to treat Ebola virus infections? A lesson from the field published pages: 9-15, ISSN: 1879-6257, DOI: 10.1016/j.coviro.2017.03.003	Current Opinion in Virology 24	2019-07-02
2016	Boubacar Diallo, Daouda Sissoko, Nicholas J. Loman, Hadja AÃ¯ssatou Bah, Hawa Bah, Mary Claire Worrell, lya Saidou Conde, Ramata Sacko, Samuel Mesfin, Angelo Loua, Jacques Katomba Kalonda, Ngozi A. Erondu, Benjamin A. Dahl, Susann Handrick, Ian Goodfellow, Luke W. Meredith, Matthew Cotten, Umaru Jah, Raoul Emeric Guetiya Wadoum, Pierre Rollin, N\'Faly Magassouba, Denis Malvy, Xavier Anglaret, Miles Resurgence of Ebola Virus Disease in Guinea Linked to a Survivor With Virus Persistence in Seminal Fluid for More Than 500 Days published pages: 1353-1356, ISSN: 1058-4838, DOI: 10.1093/cid/ciw601	Clinical Infectious Diseases 63/10	2019-07-02
2015	Vincent Madelain, Lisa Oestereich, Frederik Graw, Thi Huyen Tram Nguyen, Xavier de Lamballerie, France MentrÃ©, Stephan GÃ¼nther, Jeremie Guedj Ebola virus dynamics in mice treated with favipiravir published pages: 70-77, ISSN: 0166-3542, DOI: 10.1016/j.antiviral.2015.08.015	Antiviral Research 123	2019-07-02
2015	Paul Benkimoun, Gilbert Potier, Michel Janssens, FrÃ©dÃ©ric Le Marcis et Antoine Petibon Ebola : chronique dâ€™une catastrophe annoncÃ©e published pages: , ISSN: 2105-2522, DOI:	Humanitaire	2019-07-02
2017	Daouda Sissoko, Mory KeÃ¯ta, Boubacar Diallo, Negar Aliabadi, David L. Fitter, Benjamin A. Dahl, Joseph Akoi Bore, Fara Raymond Koundouno, Katrin Singethan, Sarah Meisel, Theresa Enkirch, Antonio Mazzarelli, Victoria Amburgey, Ousmane Faye, Amadou Alpha Sall, Nâ€™Faly Magassouba, Miles W. Carroll, Xavier Anglaret, Denis Malvy, Pierre Formenty, Raymond Bruce Aylward, Sakoba KeÃ¯ta, Mamoudou Harouna Ebola Virus Persistence in Breast Milk After No Reported Illness: A Likely Source of Virus Transmission From Mother to Child published pages: ciw793, ISSN: 1058-4838, DOI: 10.1093/cid/ciw793	Clinical Infectious Diseases	2019-07-02
2015	SylvainÂ Landry Faye Lâ€™Â«Â exceptionnalitÃ©Â Â» dâ€™Ebola et les Â«Â rÃ©ticencesÂ Â» populaires en GuinÃ©e-Conakry. RÃ©flexions Ã partir dâ€™une approche dâ€™anthropologie symÃ©trique published pages: , ISSN: 2111-5028, DOI: 10.4000/anthropologiesante.1796	Anthropologie et SantÃ© 11	2019-07-02
2017	Gomez-Temesio Veronica; Le Marcis, FrÃ©dÃ©ric La mise en camp de la GuinÃ©e. Ebola et l\'expÃ©rience postcoloniale published pages: 57-90, ISSN: 0439-4216, DOI:	L\'Homme - Revue franÃ§aise d\'anthropologie, Ã‰ditions de l\'EHESS 2017	2019-07-02
2016	Vincent Madelain, JÃ©rÃ©mie Guedj, France MentrÃ©, Thi Huyen Tram Nguyen, FrÃ©dÃ©ric Jacquot, Lisa Oestereich, Takumi Kadota, Koichi Yamada, Anne-Marie Taburet, Xavier de Lamballerie, HervÃ© Raoul Favipiravir Pharmacokinetics in Nonhuman Primates and Insights for Future Efficacy Studies of Hemorrhagic Fever Viruses published pages: e01305-16, ISSN: 0066-4804, DOI: 10.1128/AAC.01305-16	Antimicrobial Agents and Chemotherapy 61/1	2019-07-02
2015	NaÃ¯m Bouazza, Jean-Marc Treluyer, Frantz Foissac, France MentrÃ©, Anne-Marie Taburet, JÃ©rÃ©mie Guedj, Xavier Anglaret, Xavier de Lamballerie, Sakoba KeÃ¯ta, Denis Malvy, Pierre Frange Favipiravir for children with Ebola published pages: 603-604, ISSN: 0140-6736, DOI: 10.1016/S0140-6736(15)60232-X	The Lancet 385/9968	2019-07-02
2018	Guedj J, Piorkowski G, Jacquot F, Madelain V, Nguyen T-H-T, Rodallec A, Gunther S, Carbonelle C, MentrÃ© F, Raoul H, de Lamballerie X. Antiviral efficacy of favipiravir against Ebola virus in cynomolgus macaques. published pages: , ISSN: , DOI:		2019-07-02
2015	Yazdan Yazdanpanah, Peter Horby, Johan van Griensven, France Mentre, Vinh-Kim Nguyen, Jean Marie Denis Malvy, Jake Dunning, Daouda Sissoko, Jean-Francois Delfraissy, Yves Levy Drug assessment in the Ebola virus disease epidemic in west Africa published pages: 1258, ISSN: 1473-3099, DOI: 10.1016/S1473-3099(15)00344-8	The Lancet Infectious Diseases 15/11	2019-07-02
2017	Sylvain Laundry Faye Confrontations des Â« grammaires Â» de la Â«participationÂ» communautaire en contexte dâ€™urgence sanitaire dâ€™Ebola en GuinÃ©e Conakry published pages: , ISSN: , DOI:		2019-07-02
2016	Vincent Madelain, Thi Huyen Tram Nguyen, Anaelle Olivo, Xavier de Lamballerie, JÃ©rÃ©mie Guedj, Anne-Marie Taburet, France MentrÃ© Ebola Virus Infection: Review of the Pharmacokinetic and Pharmacodynamic Properties of Drugs Considered for Testing in Human Efficacy Trials published pages: 907-923, ISSN: 0312-5963, DOI: 10.1007/s40262-015-0364-1	Clinical Pharmacokinetics 55/8	2019-07-02
2015	France MentrÃ©, Anne-Marie Taburet, Jeremie Guedj, Xavier Anglaret, Sakoba KeÃ¯ta, Xavier de Lamballerie, Denis Malvy Dose regimen of favipiravir for Ebola virus disease published pages: 150-151, ISSN: 1473-3099, DOI: 10.1016/S1473-3099(14)71047-3	The Lancet Infectious Diseases 15/2	2019-07-02
2015	FrÃ©dÃ©ric Le Marcis, Vinh-Kim Nguyen An Ebola Photo Essay published pages: , ISSN: , DOI:	Limn - Issue Number Five: Ebola\'s Ecologies Five	2019-07-02

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "REACTION" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "REACTION" are provided by the European Opendata Portal: CORDIS opendata.